A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relaps
A phase 2 trial of JNJ-79635322, Tocilizumab in multiple myeloma, run by Janssen Research & Development, LLC, now recruiting.
Overview
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT07589634 by Janssen Research & Development, LLC, with 230 participants planned, started 2026-06-30 and due to reach its primary completion in 2027-12-31. Interventions recorded: Ramantamig, Tocilizumab, Placebo. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Shares JNJ-79635322, Johnson & Johnson, Multiple myeloma.
- TrialA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Shares JNJ-79635322, Johnson & Johnson, Multiple myeloma.
- TrialA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Shares JNJ-79635322, Johnson & Johnson, Multiple myeloma.
- TrialA Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multi
Shares Tocilizumab, Multiple myeloma.
- TrialA Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Shares Johnson & Johnson, Multiple myeloma.
- TreatmentSiltuximab
Shares Tocilizumab, Johnson & Johnson.
- TrialA Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Shares Johnson & Johnson, Multiple myeloma.
- TrialA Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Shares Johnson & Johnson, Multiple myeloma.